94 related articles for article (PubMed ID: 9110778)
1. Second-line therapy.
Nurs Stand; 1997 Feb; 11(21):28. PubMed ID: 9110778
[No Abstract] [Full Text] [Related]
2. New options for the treatment of advanced ovarian cancer.
Dunton CJ
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-2-S5-11. PubMed ID: 9122739
[TBL] [Abstract][Full Text] [Related]
3. Topotecan and the treatment of recurrent ovarian cancer: is there a role for granulocyte colony-stimulating factor?
Saltz L; Janik JE
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-26-S5-30. PubMed ID: 9122740
[TBL] [Abstract][Full Text] [Related]
4. Topotecan in platinum- and paclitaxel-resistant ovarian cancer.
Swisher EM; Mutch DG; Rader JS; Elbendary A; Herzog TJ
Gynecol Oncol; 1997 Sep; 66(3):480-6. PubMed ID: 9299264
[TBL] [Abstract][Full Text] [Related]
5. Topotecan hydrochloride for metastatic ovarian cancer.
Med Lett Drugs Ther; 1996 Oct; 38(986):96-7. PubMed ID: 8906133
[No Abstract] [Full Text] [Related]
6. Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapy.
Bookman MA
Oncologist; 1999; 4(2):87-94. PubMed ID: 10337378
[TBL] [Abstract][Full Text] [Related]
7. Topotecan: an important new drug in the management of ovarian cancer.
Markman M
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-1. PubMed ID: 9122736
[No Abstract] [Full Text] [Related]
8. Efficacy and safety of topotecan in the treatment of advanced ovarian carcinoma.
ten Bokkel Huinink W; Carmichael J; Armstrong D; Gordon A; Malfetano J
Semin Oncol; 1997 Feb; 24(1 Suppl 5):S5-19-S5-25. PubMed ID: 9122738
[TBL] [Abstract][Full Text] [Related]
9. [Early results of topotecan therapy in patients with recurrent ovarian cancer].
Lehoczky O; Bagaméri A; Lehoczky G; Pulay T
Orv Hetil; 2002 Apr; 143(16):825-8. PubMed ID: 12053883
[TBL] [Abstract][Full Text] [Related]
10. Treatment of recurrent ovarian cancer: increasing options--"recurrent" results.
Ozols RF
J Clin Oncol; 1997 Jun; 15(6):2177-80. PubMed ID: 9196128
[No Abstract] [Full Text] [Related]
11. Profound thrombocytopenia in previously treated patients with recurrent ovarian carcinoma receiving topotecan.
Cass I; Kuo DY; Fields AL; Runowicz CD; Goldberg GL
Gynecol Oncol; 1998 May; 69(2):175-8. PubMed ID: 9600828
[No Abstract] [Full Text] [Related]
12. [Second line treatments of cancers of the ovary].
Extra JM; Cottu PH
Rev Prat; 1997 Jun; 47(11):1217-20. PubMed ID: 9238818
[TBL] [Abstract][Full Text] [Related]
13. Second-line therapy for potentially platinum-sensitive recurrent ovarian cancer: what is optimal treatment?
Markman M
Gynecol Oncol; 2001 Apr; 81(1):1-2. PubMed ID: 11277641
[No Abstract] [Full Text] [Related]
14. Haematological evaluation of weekly therapy with topotecan for the treatment of recurrent ovarian cancer resistant to platinum-based therapy.
Largillier R; Valenza B; Ferrero JM; Novo C; Creisson A; Lesbats G; Mari V; Hebert C; Chamorey E
Oncology; 2007; 73(3-4):177-84. PubMed ID: 18418010
[TBL] [Abstract][Full Text] [Related]
15. Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.
Dark GG; Calvert AH; Grimshaw R; Poole C; Swenerton K; Kaye S; Coleman R; Jayson G; Le T; Ellard S; Trudeau M; Vasey P; Hamilton M; Cameron T; Barrett E; Walsh W; McIntosh L; Eisenhauer EA
J Clin Oncol; 2005 Mar; 23(9):1859-66. PubMed ID: 15699482
[TBL] [Abstract][Full Text] [Related]
16. Topotecan demonstrates significant activity in recurrent small-cell lung cancer.
Oncology (Williston Park); 1996 Jan; 10(1):111. PubMed ID: 8924362
[No Abstract] [Full Text] [Related]
17. [Ovarian cancer. The new chemotherapeutic agents].
Catimel G; Talon A
Soins; 1995 Oct; (599):20-2, 24-5. PubMed ID: 8701349
[No Abstract] [Full Text] [Related]
18. Advanced ovarian cancer: a clinical update on first-line treatment, recurrent disease, and new agents.
Ozols RF
J Natl Compr Canc Netw; 2004 Sep; 2 Suppl 2():S60-73. PubMed ID: 19780247
[TBL] [Abstract][Full Text] [Related]
19. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
20. Weekly topotecan for recurrent platinum resistant ovarian cancer.
Abushahin F; Singh DK; Lurain JR; Grendys EC; Rademaker AW; Schink JC
Gynecol Oncol; 2008 Jan; 108(1):53-7. PubMed ID: 17904208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]